Recent Articles in Free Articles

Deals and Financings

• Jiangsu Hengrui Pharma out-licensed global rights (ex-China) for its next-gen PARP1 inhibitor to Germany’s Merck for a $170 million upfront payment and up to $1.5 billion in milestones;
• BioLineRx, an Israeli biotech, out-licensed China rights to a stem cell mobilizer for multiple myeloma and stem cell diseases to Guangzhou Gloria Biosciences in a $280 million agreement;
• AnHeart Therapeutics, a New York-Shanghai biopharma, sold Japanese rights for its lead drug, a ROS1 tyrosine kinase inhibitor to Nippon Kayaku for $40 million upfront plus milestones and royalties;
• Suzhou CStone Pharma out-licensed China rights for nofazinlimab, the company’s anti-PD-1 antibody, to a subsidiary of 3SBio for $8 million upfront and $14 million in near term milestones;
• Shenzhen Mellow Hope Pharm and Rational Vaccines of Massachusetts partnered to develop, manufacture and commercialize live vaccines for herpes simplex viruses;

Trials and Approvals

• Shanghai Junshi Bio and Coherus BioSciences announced the US FDA approved their partnered PD-1 drug to treat two nasopharyngeal carcinoma indications without any US trials;
• Suzhou Innovent reported its GLP-1R/GCGR dual agonist reduced body weight by 18.6% in obese patients after 48 weeks of treatment in a China Phase II trial;
• HuidaGene Therapeutics, a Shanghai-New Jersey gene editing company, dosed the first patient in a China-US Phase I/IIa clinical trial for inherited blindness caused by RPE65 mutations;
• Ractigen Therapeutics of Jiangsu presented positive preclinical results of its short duplex RNA technology for a gene therapy to treat Duchenne muscular dystrophy;
• Shenzhen Chipscreen Biosciences was approved to start China clinical trials of its novel oral therapy for psoriasis, a small molecule TYK2 inhibitor.
  
  Share this with colleagues:  
  
  

Deals and Financings

• Hansoh Pharma sold ex-China rights for its B7-H4 ADC to GSK in a $1.57 billion deal ($85 million upfront), plus royalties on any sales;
• OrbiMed raised $751 million in commitments for its OrbiMed Asia V fund, a virtual repeat to a March 2022 close of an earlier fund, Asia IV;
• LianBio will sell greater China rights to a cardiovascular drug for $350 million to BMS, which acquired rest-of-the-world rites by buying MyoKardia for $13.1 billion.
• San Francisco's Aiolos Bio closed a $245 million Series A round to develop respiratory drugs including a Phase II asthma therapy in-licensed from Jiangsu Hengrui in a $1 billion deal;
• Shanghai Henlius Biotech out-licensed Europe/India rights for its anti-PD-1, Hansizhuang, to its partner Intas Pharmaceuticals in a $200 million agreement;
• Sirius Therapeutics closed a $60 million Series-B financing to advance clinical development of the company’s novel siRNA therapeutics for cardiovascular needs;
• Angitia, a Guangzhou and Woodland Hills, CA Biopharma, raised $46 million Series B extension for therapies that address unmet needs in serious musculoskeletal diseases;

Trials and Approvals

• Sichuan Kelun-Biotech reported positive results from a China Phase II trial of its TROP2-ADC as a second-line therapy for patients with HR+/HER2- metastatic breast cancer;
• AnHeart Therapeutics, a New York-Shanghai biopharma, reported its next-gen ROS1 inhibitor shrank tumors in 92% of treatment-naïve patients with ROS1-positive NSCLC;
• Virion and its JV partner, Ocean Biomedical started a Phase 1b Hong Kong-New Zealand trial of an immunotherapy as a functional cure chronic for HBV.
  
  Share this with colleagues:  
  
  

Deals and Financings

• Suzhou MediLink Therapeutics out-licensed global rights (ex-China) for its HER3 antibody-drug conjugate candidate to Germany’s BioNTech in a $1.1 billion agreement ($70 million upfront);
• BioMap, a three-year old Beijing AI drug discovery company, will collaborate with France’s Sanofi to co-develop new protein therapies in a $1 billion deal;
• Chongqing Zhifei Biological partnered China sales of a GSK shingles vaccine, Shingrix, agreeing to double sales and purchase $3 billion of the vaccine over the next three years;
• Suzhou Gritgen Therapeutics held an opening ceremony of its commercial gene therapy GMP facility in Suzhou Industrial Park after it completed validation;

Trials and Approvals

• Suzhou Ascentage Pharma was approved to start a pivotal global Phase III study of its Bcl-2 inhibitor APG-2575 as a first-line therapy for lymphocytic leukemia;
• Jiangsu Atom Bioscience dosed the first patient in a Phase IIb/III trial of its lead drug, ABP-671, a novel oral URAT1 inhibitor for chronic gout;
• Guangzhou Akeso published positive results in The Lancet Oncology of a Phase Ib/II clinical trial of its PD-1/CTLA-4 bispecific antibody ;
• Suzhou Kintor Pharma announced China approval for a Phase II trial of its small molecule Hedgehog/SMO inhibitor, a proposed therapy for idiopathic pulmonary fibrosis;
• Shanghai GenFleet Therapeutics started a Phase Ib/II trial of a selective CDK9 inhibitor to treat relapsed/refractory peripheral T-cell lymphomas;
• Shanghai I-Mab reported positive early results from a US/Korea Phase I trial of a novel PD-L1 x 4-1BB bispecific for solid tumors resistant to PD-(L)1 therapies.
  
  Share this with colleagues:  
  
  

Deals and Financings

• Jiangsu QYuns Therapeutics filed for a Hong Kong IPO to advance its portfolio of nine biologic antibody drugs for autoimmune and allergic diseases;
• Taiwan’s PharmaEssentia acquired global rights to a myeloid immune checkpoint antibody for solid tumors from WuXi Biologics Ireland;

Trials and Approvals

• Biogen of Cambridge, MA announced US approval for an Actemra® biosimilar for arthritis in-licensed from Guangzhou's Bio-Thera;
• Everest Medicine reported positive data for Asian patients in a Phase III study of treatment for IgA Nephropathy, a cause of kidney disease;
• Arctic Vision, a Shanghai ophthalmology biopharma, completed enrollment in a China Phase III trial of a therapy for uveitic macular edema, which causes blindness;
• Suzhou Transcenta was approved to start a US Phase III trial of its CLDN18.2 antibody in patients with metastatic gastric or gastroesophageal adenocarcinoma;
• Guangzhou Magpie Pharma reported its lead candidate, TBN, improved some key markers of ALS disease progression in a China Phase II trial.
  
  Share this with colleagues: